B-RAF is a therapeutic target in melanoma. - Wikidata - wikimedia - TriplyDB

B-RAF is a therapeutic target in melanoma.

B-RAF is a therapeutic target in melanoma.

http://www.wikidata.org/entity/Q40543086

about

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions Analysis of the genome to personalize therapy for melanoma Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms Melanoma-restricted genes The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Melanoma: oncogenic drivers and the immune system Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Emerging targeted therapies for melanoma treatment (review)Melanoma: new insights and new therapies Current and future trials of targeted therapies in cutaneous melanoma Melanoma: from mutations to medicine Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinase An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors BRAF mutation predicts sensitivity to MEK inhibition BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Melanoma genetics and the development of rational therapeutics.Thyroid cancer: current molecular perspectives.A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.BRAF drives synovial fibroblast transformation in rheumatoid arthritis.A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.Phosphoproteomics in cancer

P2860

Q21004109-044EDE05-7850-4FAD-A3AB-E29591A6A70B Q24601008-2456C071-2B7A-4910-94B9-C4D36894B882 Q24674150-B1E1C466-3361-43CD-8B7A-5DEBF198B3A6 Q24793788-8525ED1B-8CA3-4E0F-9597-7678A54C0683 Q26747247-E8267B8A-8D67-426F-987C-2DEEB71F2503 Q26775598-A12150C5-4319-4661-84F6-3AD6A676CC51 Q26823978-E3C52B58-26B0-41D6-BD3E-21F95FA1DEB6 Q26829997-069FC55B-B882-419C-8B28-9106C3D86792 Q26853127-8F6E445F-D8FF-44DE-AF57-5780C818BDFC Q27022355-00F621A0-D689-4DBA-80FA-BF9C38BF654D Q27024061-332084AA-2A52-4C17-BAC4-FD73455B3069 Q27851801-6E7F815B-53AC-49D6-BA77-0AD33B0EC7BB Q28259285-BB04BC07-82FC-4672-8626-0756039B3821 Q28265862-E141B537-C83F-4F5E-B0B1-62C1E5D66226 Q28512744-7D836B2B-AFC6-456F-A0E3-9C4AC9EE88BB Q28535159-2F05DFC4-8DB9-42DF-B0AF-907772A2AC0E Q28538778-9A11737D-1D18-44E8-A49A-48465A81198A Q28607031-7DC93D4B-DDF1-4421-8FDC-CD07414C05AB Q28647625-07763B6E-18E7-4AEC-86C2-CA2505F81B29 Q29614281-ED81CB3C-A410-48BC-A429-8316F4792AAD Q30458424-AA59611D-1CD2-4D1D-97BF-F3DB3031B77D Q33352015-028BB2FD-9329-4FE7-9B48-7A60E5C3D44B Q33399049-4D4E8233-FB0A-49E2-A63A-6BA6F536869A Q33514138-7E883B41-CE9E-4A14-9977-0841B5040AF9 Q33560698-B90E5A66-A3CD-45FF-868F-7850EC8B8169 Q33627135-01EAC744-D50D-4620-96BB-7E6DA2289B83 Q33688428-3E2C2EA5-77A8-4E9F-A194-B27EACB909E6 Q33726956-27160CD0-A785-411D-979E-023DACF64830 Q33760910-B02DE404-A8FB-4838-ACD1-EB7C520A0634 Q33785790-F45D3727-0AC3-42A1-A334-CB22C5521A0F Q33822119-C268E7AC-4B61-456B-ADE0-77A76A32550F Q33873686-CA627E8C-3AE8-4018-8985-00E6E9B228C9 Q33906093-F0850286-0856-4B18-947A-F8157A05774B Q34069302-7F80B895-337C-4837-B739-98ADF66C4465 Q34084873-1516BE52-A35B-4FA2-B3E2-F11EFE6A24D8 Q34088265-EFDC8D28-90F9-47B9-8A0B-844457D1D0FE Q34222257-1530B167-DD9C-406C-9CFB-CE9ECB3D6143 Q34251026-82742639-9B3E-4087-B897-157C74E0BC60 Q34402062-86078DFA-54A2-4026-A574-B9FDA635A6B3 Q34539788-9A164ACB-21B6-4F8A-9E13-6A2CBFB79EC5

P2860

B-RAF is a therapeutic target in melanoma.

http://www.wikidata.org/entity/Q40543086

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

B-RAF is a therapeutic target in melanoma.

@en

type

label

B-RAF is a therapeutic target in melanoma.

@en

prefLabel

B-RAF is a therapeutic target in melanoma.

@en

P1433

Q40543086-CADFDDF3-7A1F-4176-B79E-8E73B828D047

P1476

Q40543086-D1AFE323-CCF6-4348-8903-AFBAB948FB7A

P2093

Q40543086-06249C1E-248B-4208-9A00-E33D54BDFA6E

Q40543086-08C11615-1A0C-4A78-A1AB-500819F4B9B5

Q40543086-0C0C8201-AEFE-49DE-96ED-025C120E196A

Q40543086-3A301028-B5CF-4BA0-BE13-2B66D20DBA05

Q40543086-79DBF59A-3FE7-4788-B253-844D13AA6D98

Q40543086-8252DAB8-9352-46CC-87DF-7613BB7EA50C

Q40543086-9C0DAFE5-2DE5-42B9-AFF1-EE945F158EF9

Q40543086-AA1536C2-EABA-4B6D-A827-311D6320E82D

Q40543086-AA87853B-5928-4A56-BC51-701FF3BFAB08

Q40543086-BB5A9214-BE6A-4C8C-9B11-F0B7DE88AC61

P2888

Q40543086-ECF65AE2-1F06-426B-80EA-94E957938FD8

P304

Q40543086-83B6FEAB-3D5D-420E-A7F7-8179B2C742A8

P31

Q40543086-23AFC1AC-5E56-493C-A771-F324DFD77FA3

P356

Q40543086-CA231B2D-32C3-44E7-AA7B-303911F2F1AE

P407

Q40543086-8268BA07-4E05-4C2D-B51D-71D3EDA20106

P433

Q40543086-C8A1C42D-5BA7-4C04-B274-265C2D347230

P478

Q40543086-FF93827D-F3B4-4115-BF14-2FB5685FE76D

P50

Q40543086-71FDC102-A09A-42F4-AF0D-1F848B35EF49

Q40543086-BBF129E4-91A0-49A4-A78D-E3E3C3AC3ED6

P577

Q40543086-EEF26FE1-26D9-41B9-9A25-813300175DEF

P5875

Q40543086-6E2AEEEF-5E12-4AA4-BA6C-AFE15321DAC1

P6179

Q40543086-F46D5186-0D67-411F-8C37-E26847F72FAF

P698

Q40543086-E592A64E-CE1C-4102-9ED2-627F2AA2EA63

P356

P1433

P1476

B-RAF is a therapeutic target in melanoma.

@en

P2093

Antonio Chiloeches

http://www.w3.org/2001/XMLSchema#string

Christopher J Marshall

http://www.w3.org/2001/XMLSchema#string

Dan Niculescu-Duvaz

http://www.w3.org/2001/XMLSchema#string

Douglas Hedley

http://www.w3.org/2001/XMLSchema#string

Frank Friedlos

http://www.w3.org/2001/XMLSchema#string

Ian Scanlon

http://www.w3.org/2001/XMLSchema#string

Jan Martin

http://www.w3.org/2001/XMLSchema#string

Lesley Ogilvie

http://www.w3.org/2001/XMLSchema#string

Maria Karasarides

http://www.w3.org/2001/XMLSchema#string

Robert Hayward

http://www.w3.org/2001/XMLSchema#string

P2888

P304

6292-6298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1207785

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Caroline J Springer

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8498826

http://www.w3.org/2001/XMLSchema#string

P6179

1041507679

http://www.w3.org/2001/XMLSchema#string

P698

15208680

http://www.w3.org/2001/XMLSchema#string